Cognition Therapeutics
CGTX----
Cognition Therapeutics (CGTX)
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Cognition Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 1, 2026Price forecast
$3.50264.51%
Forecast & RatingStrong buy
4analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Global Report · 2 days ago, 04:18 AM
US Equities Tracker: Restructuring and Pipeline Milestones Shape H2 2026
- Global Report · Jul 21 at 04:13 AM
The Unbundling of the Long Tail: Structural Realities at the Edges of the Value Chain
- PUBT · Jul 13 at 06:31 AM
Cognition Therapeutics posts press release on B. Riley summit fireside chat to IR website
- PUBT · Jun 25 at 08:02 AM
Hippo deploys Cognition’s Devin AI software engineer across insurance operations
- benzinga_article · Jun 24 at 12:05 PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
- PUBT · Jun 24 at 06:30 AM
Cognition Therapeutics targets mid-2027 start for Phase 3 zervimesine trial in DLB psychosis
